Value of new biomarkers for safety testing in drug development

Expert Review of Molecular Diagnostics

Volumn 9, Issue 6, 2009, Pages 531-536

  Hewitt, Philip ^a   Herget, Thomas ^b  

^a Merck Serono GmbH   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CLUSTERIN; CYSTATIN C; GENOMIC DNA; KIDNEY INJURY MOLECULE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

BIOLOGY; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; EDITORIAL; ELECTROPHORESIS; EXPERIMENTAL ANIMAL; EXPERIMENTAL RAT; FOOD AND DRUG ADMINISTRATION; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY INJURY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TOXICITY TESTING; TOXICOLOGY;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOMARKERS, PHARMACOLOGICAL; DRUG DISCOVERY; HUMANS; TOXICOGENETICS;

EID: 69949188347     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.38     Document Type: Editorial

References (32)

1. Russell WMS, Burch RL. The Principles of Humane Experimental Technique. Springfield, London, UK (1959).
2. Hamadeh HK, Bushel PR, Jayadev S et al. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67, 232-240 (2002). (Pubitemid 34746476)
3. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995).
4. Ganter B, Zidek N, Hewitt PR, Müller D, Vladimirova A. Pathway analysis tools and toxicogenomics reference databases for risk assessment. Pharmacogenomics 9, 35-54 (2008). (Pubitemid 351560530)
5. Waring JF, Jolly RA, Ciurlionis R et al. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175, 28-42 (2001). (Pubitemid 32783533)
6. Steiner G, Suter L, Boess F et al. Discriminating different classes of toxicants by transcript profiling. Environ. Health Perspect. 112, 1236-1248 (2004). (Pubitemid 39199564)
7. Yao X, Panichpsal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334, 115-124 (2007). (Pubitemid 47262919)
8. Nicholson JK, Lindon JC, Holmes E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR data. Xenobiotica 29, 1181-1189 (1999).
9. Xu EY, Perlina A, Vu H et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chem. Res. Toxicol. 21, 1548-1561 (2008).
10. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237-244 (2002).
11. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 15(7), 1677-1689 (2004). (Pubitemid 38822046)
12. US FDA: Genomics www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/default.htm
13. Critical Path Institute; Predictive Safety Testing Consortium (PSTC) www.c-path.org/pstc.cfm
14. EMEA: First EMEA-FDA joint biomarkers qualification process www.emea.europa.eu/htms/human/mes/biomarkers.htm
15. RBM, the Biomarker testing laboratory www.rulesbasedmedicine.com
16. Novagen: WideScreen™ Rat Kidney Toxicity Assays www.emdbiosciences.com/html/NVG/home.html
17. EMEA: Committee for Medicinal Products for Human Use, Jan. 2009 www.emea.europa.eu/pdfs/human/biomarkers/7289408en.pdf
18. FDA, European Medicines Agency to Consider Additional Test Results When Assessing New Drug Safety Collaborative effort by FDA and EMEA expected to yield additional safety data www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ ucm116911.htm
19. European Commission: CORDIS. Seventh framework programme www.cordis.europa.eu/FP7/home.html
20. US FDA. Critical Path Initiative www.fda.gov/oc/initiatives/criticalpath
21. Medicamentos Innovadores. Spanish platform www.medicamentosinnovadores. org
22. TI Pharma. www.tipharma.com/home.html
23. European Clinical Research Infrastructures Network www.ecrin.org
24. 3Rs studies considered for DTI Safety Biomarker funding. Research into safety biomarkers may have implications for the 3Rs (reduction, refinement and replacement of animals in research) www.nc3rs.org.uk/news.asp?id=241
25. Center for Biomedical Innovation http://web.mit.edu/cbi/
26. Toxicogenomics Project in Japan Web Site wwwtgp.nibio.go.jp/index-e.html
27. Vision of Japan Health Science Foundation www.jhsf.or.jp/English/vision. html
28. Japan Medical Association Center for Clinical Trials www.jmacct.med.or. jp/english/index.html
29. Chemical effects in biological systems http://cebs.niehs.nih.gov
30. Metabolomics.net. The metabolic portal www.metabolomics.net
31. The Health and Environmental Sciences Institute www.hesiglobal.org
32. InnoMed PredTox www.innomed-predtox.com